Bagaria et al use as an example the triple-negative phenotype defined by the absence of estrogen
receptor, progesterone receptor, and human epidermal growth factor 2 to examine whether such
inclusion improves the prognostic accuracy of TNM staging for breast cancer.
This case series uses review of medical records to report on potential immunohistochemical prognostic molecular markers to determine their prognostic and therapeutic utility for patients with vascular leiomyosarcomas.
Gangi et al compare the outcomes of breast-conserving therapy for patients with triple-negative breast cancer (TNBC) with those of patients with non-TNBC subtypes, specifically luminal A, luminal B, and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) enriched.